mRNA vaccine encoding fusion antigen against Mpox and severe acute respiratory syndrome coronavirus 2
US12324835B1 · kind B1 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 16, 2025 |
| Grant date | Jun 10, 2025 |
| Priority date | — |
| Expiry date | Jan 16, 2045 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/20034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An mRNA molecule is disclosed. The mRNA molecule contains a polynucleotide encoding an M1R antigen of Mpox and a polynucleotide encoding an RBD antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and further contains a polynucleotide encoding an A35R antigen of Mpox. An application of the mRNA molecule in the preparation of an mRNA vaccine against Mpox or SARS-CoV-2 is further disclosed. Compared to an mRNA vaccine encoding separately corresponding antigens, the provided mRNA vaccine encoding a fusion antigen can induce considerable or even higher-level neutralizing antibody responses against Mpox and SARS-CoV-2, and provides 100% immune protection against the lethal challenge of ectromelia virus. The vaccine is obtained by synthesizing a single mRNA molecule and encapsulating the single mRNA within lipid nanoparticles. Therefore, the single-component fusion mRNA vaccine has a wider application prospect than multivalent mRNA vaccine compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.